2025 brought a number of important refinements to international regulatory guidance that directly affect how clinical documentation is prepared. Below is a focused look at the changes worth tracking.
1. ICH E6(R3): renewed expectations for the conduct of GCP
The finalized ICH E6(R3) guideline took center stage in 2025, replacing the longstanding R2 with a principles-based, quality-by-design approach to GCP.
Key change: Greater emphasis on critical-to-quality factors, sponsor oversight of decentralized elements, and risk-proportionate quality management.
What it means for you: Templates for Protocols, Investigator's Brochures, and monitoring plans need to reflect the new principles. Platforms like ClinScriptum can help by maintaining a structured Knowledge Base across the document set, so quality-relevant facts stay aligned by design.
2. EMA: refinements to bioequivalence study design
EMA continued to refine its bioequivalence guidance in 2025, with updates to expectations for highly variable drugs and complex pharmacokinetics.
Key change: Clarified approaches to washout-period calculations and the use of replicate designs for highly variable products.
What it means for you: Automated reconciliation of washout periods against half-life (T1/2) becomes more critical than ever. A protocol-design error can cause an entire study to be rejected, so catching it early is essential.
3. FDA: Project Optimus and structured electronic submissions
FDA's Project Optimus continued to push sponsors toward earlier and broader dose-optimization data, while electronic submission expectations around CDISC standards evolved further in 2025.
Key change: Stronger expectations that text, tables, and appendices in CSRs and submission documents are internally consistent and machine-readable.
What it means for you: "Digitization" of documentation is no longer a convenience but a regulatory expectation. Tools that enforce data integrity by design materially reduce the risk of information requests from health authorities.
Takeaway: International regulators continue to converge around quality-by-design and data integrity. Sponsors that adapt their processes and tooling early will avoid costly downstream rework.
